DFS of MRD^pos group. DFS in patients undergoing (A) SCT-based treatment, (B) allogeneic SCT or H/C therapy; (C) DFS in patients who converted or not to MRD^neg status after H/C or SCT. DFS probability at 4 years: SCT or H/C 0.33 versus 0 with neither (A); H/C 0.37 versus SCT 0.30 (B); MRD^neg 0.51 versus MRD^pos 0 (C).